Recurrent splanchnic and extrasplanchnic thrombotic events in patients with non-cirrhotic portal vein thrombosis associated with local factors.

Acute portal thrombus abdominal inflammation recurrence thrombophilia

Journal

Journal of hepatology
ISSN: 1600-0641
Titre abrégé: J Hepatol
Pays: Netherlands
ID NLM: 8503886

Informations de publication

Date de publication:
26 Apr 2024
Historique:
received: 12 11 2023
revised: 04 04 2024
accepted: 13 04 2024
medline: 29 4 2024
pubmed: 29 4 2024
entrez: 28 4 2024
Statut: aheadofprint

Résumé

One third of recent non-cirrhotic portal vein thrombosis are associated with local factors. The risk of rethrombosis after anticoagulation withdrawal is unknown. We aimed to determine factors associated with splanchnic or extrasplanchnic new thrombotic events in that setting. Retrospective study including recent non-cirrhotic portal vein thrombosis associated with local factors. High and low prothrombotic risk factors, prespecified according to Riport study criteria, were assessed. Quantitative and qualitative variables are presented as median (inter-quartile range), and absolute and relative frequencies respectively. Univariate and multivariate Cox models assessed the influence of different variables on the occurrence of a new thrombotic event. At baseline, 83/154 (53.9%) had at least one prothrombotic factor including 50 (32.5%) high-risk and 33 (21.4%) low-risk prothrombotic factors. Oestrogen containing contraception was discontinued in all patients. During follow up, 63/140 (45%) patients had at least one prothrombotic factor, including 47 (33.6%) with a high risk, and 16 (11.4%) a low risk prothrombotic factor. Seventeen new thrombotic events occurred after a median follow-up of 52 (IQR 14-62) (min-max 3.0-69.0) months. New thrombosis were associated with high risk factors (HR 3.817, 95% CI [1.303-11.180], p= 0.015), but inversely related to recanalization (HR 0.222, 95% CI [0.078-0.635], p=0.005) and anticoagulation (HR 0.976, 95% CI [0.956-0.995], p=0.016). When a high-risk factor was present a new thrombotic event occurred in 7.4%, 14.6%, 14.6% and 28.8% of patients at 1, 3, 5 and 7 years under anticoagulants compared to 21.2%, 21.2%, 58% and 58% without anticoagulants. In recent non-cirrhotic portal vein thrombosis associated with local factors, high risk factors for thrombosis are associated with new thrombotic events. Permanent anticoagulation appears beneficial in this high-risk situation. In noncirrhotic portal vein thrombosis (NCPVT) associated with local factors, systematic screening for prothrombotic factors is recommended, but prevalence of the latter is not clearly established, and the risk of recurrent intra or extra splanchnic thromboembolism is poorly described. Thus, interest in permanent anticoagulation therapy is still pending. NCPVT associated with local factors, is a matter of concern for hepatologists, gastroenterologists and digestive surgeons. Due to a lack of knowledge, practices are heterogeneous. Our findings highlight that systematic screening for prothrombotic factors in NCPVT is strongly needed even when associated with local factors, as it may justify long-term anticoagulation therapy for the prevention of new intra or extra-splanchnic thrombotic events in at least one-third of cases. The interest in long-term anticoagulation should be investigated prospectively in the absence of prothrombotic factors with high risk of thrombosis. NCT0536064.

Identifiants

pubmed: 38679069
pii: S0168-8278(24)00284-8
doi: 10.1016/j.jhep.2024.04.016
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024. Published by Elsevier B.V.

Auteurs

Isabelle Ollivier-Hourmand (I)

Hepatology unit, University Hospital Côte de Nacre, Caen, France. Electronic address: ollivierhourmand-i@chu-caen.fr.

Louise Lebedel (L)

Hepatology unit, University Hospital Côte de Nacre, Caen, France. Electronic address: lebedel-i@chu-caen.fr.

Berta Bartroli Alabau (B)

Barcelona Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clínic, Universitat de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Barcelona, Spain; Health Care Provider of the European Reference Network on Rare Liver Disorders (ERN-Liver), Spain. Electronic address: Bertabartroli@gmail.com.

Odile Goria (O)

Hepatology unit, University Hospital Charles-Nicolle, Rouen, France. Electronic address: odile.goria@chu-rouen.fr.

Christophe Bureau (C)

Hepatology unit, University Hospital Purpan, Toulouse, France. Electronic address: bureau-c@chu-toulouse.fr.

Jérome Dumortier (J)

Hepatology unit, University Hospital Edouard Herriot, Lyon, France. Electronic address: jerome.dumortier@chu-lyon.fr.

Alexandra Heurgué (A)

Hepatology unit, University Hospital Robert Debré, Reims, France. Electronic address: aheurgue@chu-reims.fr.

Christine Silvain (C)

Hepatology unit, University Hospital, Poitiers, France. Electronic address: c.silvain@chu-poitiers.fr.

Victor De-Ledinghen (V)

Hepatology unit, University Hospital Haut Levêque & INSERM U1312 ; Université de Bordeaux, Bordeaux, France. Electronic address: victor.deledinghen@chu-bordeaux.fr.

Pierre-Emmanuel Rautou (PE)

Université de Paris, AP-HP, Hôpital Beaujon, Service d'Hépatologie, DMU DIGEST, Centre de Référence des Maladies Vasculaires du Foie, FILFOIE, ERN RARE-LIVER, Centre de recherche sur l'inflammation, Inserm, UMR 1149, Paris, France. Electronic address: pierre-emmanuel.rautou@aphp.fr.

Audrey Payancé (A)

Université de Paris, AP-HP, Hôpital Beaujon, Service d'Hépatologie, DMU DIGEST, Centre de Référence des Maladies Vasculaires du Foie, FILFOIE, ERN RARE-LIVER, Centre de recherche sur l'inflammation, Inserm, UMR 1149, Paris, France. Electronic address: audrey.payance@aphp.fr.

Teresa García Ballester (T)

Cardiology Department, Hospital Clínico Universitario, Universitat de Valencia, INCLIVA, Valencia, Spain. Electronic address: teresagarciaballester@gmail.com.

Edilmar Alvarado-Tapias (E)

Centro De Investigación Biomédica Red De Enfermedades Hepáticas y Digestivas (CIBERehd)), Spain; Servei De Patologia Digestiva, Hospital De La Santa Creu I Sant Pau, Spain. Electronic address: EAlvaradoT@santpau.cat.

Virginia Hernández-Gea (V)

Barcelona Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clínic, Universitat de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Barcelona, Spain; Health Care Provider of the European Reference Network on Rare Liver Disorders (ERN-Liver), Spain. Electronic address: VIHERNANDEZ@clinic.cat.

Dominique Valla (D)

Université de Paris, AP-HP, Hôpital Beaujon, Service d'Hépatologie, DMU DIGEST, Centre de Référence des Maladies Vasculaires du Foie, FILFOIE, ERN RARE-LIVER, Centre de recherche sur l'inflammation, Inserm, UMR 1149, Paris, France. Electronic address: dominique.valla@aphp.fr.

Kamal Zekrini (K)

Université de Paris, AP-HP, Hôpital Beaujon, Service d'Hépatologie, DMU DIGEST, Centre de Référence des Maladies Vasculaires du Foie, FILFOIE, ERN RARE-LIVER, Centre de recherche sur l'inflammation, Inserm, UMR 1149, Paris, France. Electronic address: kamal.zekrini@aphp.fr.

Thi Thu Nga Nguyen (TTN)

Hepatology unit, University Hospital Côte de Nacre, Caen, France. Electronic address: nguyen-ttn@chu-caen.fr.

Thong Dao (T)

Hepatology unit, University Hospital Côte de Nacre, Caen, France. Electronic address: dao-t@chu-caen.fr.

Juan Carlos Garcia Pagan (JC)

Barcelona Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clínic, Universitat de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Barcelona, Spain; Health Care Provider of the European Reference Network on Rare Liver Disorders (ERN-Liver), Spain. Electronic address: JCGARCIA@clinic.cat.

Rémy Morello (R)

Statistics Department, Hospital Côte de Nacre, Caen, France. Electronic address: morello-r@chu-caen.fr.

Aurélie Plessier (A)

Université de Paris, AP-HP, Hôpital Beaujon, Service d'Hépatologie, DMU DIGEST, Centre de Référence des Maladies Vasculaires du Foie, FILFOIE, ERN RARE-LIVER, Centre de recherche sur l'inflammation, Inserm, UMR 1149, Paris, France. Electronic address: aurelie.plessier@aphp.fr.

Classifications MeSH